FDA’s AI Shift: Why Postmarket Surveillance is Key to De-Risking
Artificial intelligence is evolving so quickly in healthcare that it’s creating both massive opportunities and a regulatory mess. The old way of getting a medical…
Artificial intelligence is evolving so quickly in healthcare that it’s creating both massive opportunities and a regulatory mess. The old way of getting a medical…
The way the FDA regulates AI health tools is finally catching up to reality. We’re shifting from a reactive, one-and-done clearance model to a system…
The field of cardiovascular digital health is changing fast, driven by a blistering pace of development and a huge uptick in regulatory activity. Anyone tracking…
The recent HeartFlow IPO, where the company raised $364.2 million, is more than just a financial headline for the tech sector; it’s a profound signal…
The rapid convergence of Big Tech’s operational prowess and the deeply personal realm of primary healthcare presents a complex challenge for regulators. As companies like…
The rapid proliferation of artificial intelligence (AI) in healthcare presents both transformative opportunities and significant regulatory challenges. For health IT professionals and clinicians navigating this…
The proliferation of artificial intelligence in healthcare promises transformative advancements, yet it simultaneously ushers in a complex regulatory landscape, particularly concerning post-market surveillance. For AI-driven…
The global landscape for AI in healthcare is rapidly converging, forcing health plan executives and health IT professionals to confront a complex web of dual…
The journey from an innovative AI algorithm in a research lab to a clinically deployable, FDA-cleared medical product is fraught with complexities, particularly for those…
The landscape of AI in healthcare is rapidly evolving, demanding a clear understanding of regulatory pathways for both innovators and investors. A critical question for…